LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

3500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-25

Study Completion Date

2031-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

NCT03403036

Psoriasis

COMPLETED PHASE4

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

NCT05132231

Psoriasis

ACTIVE_NOT_RECRUITING

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

NCT04149587

Psoriasis

COMPLETED

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603

Moderate to Severe Plaque Psoriasis

TERMINATED PHASE3

Treatment of Moderate Hidradenitis Suppurativa

NCT03910803

Hidradenitis Suppurativa

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Brodalumad exposed

1500 subjects exposes to brodalumab

Brodalumab

Intervention Type BIOLOGICAL

Brodalumab

Comparator Subjects

2000 comparator subjects

Comparator Drug (non-biologic IL-17 inhibitors)

Intervention Type DRUG

Comparator subjects treated with non-biologic IL-17 inhibitors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brodalumab

Intervention Type BIOLOGICAL

Comparator Drug (non-biologic IL-17 inhibitors)

Comparator subjects treated with non-biologic IL-17 inhibitors

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist
2. Must be at least 18 years of age or older
3. Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.

Exclusion Criteria

1. The subject is unable or unwilling to provide informed consent to participate in the registry.
2. The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).
3. The subject is restarting the eligible medication less than 12 months since receiving the last dose.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No